169 related articles for article (PubMed ID: 19807743)
1. The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility.
Sambuughin N; Capacchione J; Blokhin A; Bayarsaikhan M; Bina S; Muldoon S
Clin Genet; 2009 Dec; 76(6):564-8. PubMed ID: 19807743
[TBL] [Abstract][Full Text] [Related]
2. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
Kraeva N; Sapa A; Dowling JJ; Riazi S
Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
[TBL] [Abstract][Full Text] [Related]
3. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
[TBL] [Abstract][Full Text] [Related]
4. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
[TBL] [Abstract][Full Text] [Related]
5. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.
Dlamini N; Voermans NC; Lillis S; Stewart K; Kamsteeg EJ; Drost G; Quinlivan R; Snoeck M; Norwood F; Radunovic A; Straub V; Roberts M; Vrancken AF; van der Pol WL; de Coo RI; Manzur AY; Yau S; Abbs S; King A; Lammens M; Hopkins PM; Mohammed S; Treves S; Muntoni F; Wraige E; Davis MR; van Engelen B; Jungbluth H
Neuromuscul Disord; 2013 Jul; 23(7):540-8. PubMed ID: 23628358
[TBL] [Abstract][Full Text] [Related]
6. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
[TBL] [Abstract][Full Text] [Related]
8. Increasing the number of diagnostic mutations in malignant hyperthermia.
Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
[TBL] [Abstract][Full Text] [Related]
9. RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction.
Kruijt N; den Bersselaar LV; Snoeck M; Kramers K; Riazi S; Bongers C; Treves S; Jungbluth H; Voermans N
Curr Pharm Des; 2022; 28(1):2-14. PubMed ID: 34348614
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
[TBL] [Abstract][Full Text] [Related]
11. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations.
Knuiman GJ; Küsters B; Eshuis L; Snoeck M; Lammens M; Heytens L; De Ridder W; Baets J; Scalco RS; Quinlivan R; Holton J; Bodi I; Wraige E; Radunovic A; von Landenberg C; Reimann J; Kamsteeg EJ; Sewry C; Jungbluth H; Voermans NC
J Neurol; 2019 Apr; 266(4):876-887. PubMed ID: 30788618
[TBL] [Abstract][Full Text] [Related]
12. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees.
Davis M; Brown R; Dickson A; Horton H; James D; Laing N; Marston R; Norgate M; Perlman D; Pollock N; Stowell K
Br J Anaesth; 2002 Apr; 88(4):508-15. PubMed ID: 12066726
[TBL] [Abstract][Full Text] [Related]
13. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
[TBL] [Abstract][Full Text] [Related]
14. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
[TBL] [Abstract][Full Text] [Related]
15. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
Sambuughin N; Sei Y; Gallagher KL; Wyre HW; Madsen D; Nelson TE; Fletcher JE; Rosenberg H; Muldoon SM
Anesthesiology; 2001 Sep; 95(3):594-9. PubMed ID: 11575529
[TBL] [Abstract][Full Text] [Related]
16. Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations.
Carsana A
ScientificWorldJournal; 2013; 2013():531465. PubMed ID: 23476141
[TBL] [Abstract][Full Text] [Related]
17. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
18. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
19. Malignant hyperthermia: update on susceptibility testing.
Litman RS; Rosenberg H
JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
[TBL] [Abstract][Full Text] [Related]
20. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
